Cargando…
Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach
Chemotherapy is the mainstream treatment modality for invasive breast cancer. Unfortunately, chemotherapy-associated adverse events can result in early termination of treatment. Paradoxical effects of chemotherapy are also sometimes observed, whereby prolonged exposure to high doses of chemotherapeu...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818958/ https://www.ncbi.nlm.nih.gov/pubmed/35141145 http://dx.doi.org/10.3389/fonc.2021.783803 |
_version_ | 1784645948720283648 |
---|---|
author | Tai, Yee Kit Chan, Karen Ka Wing Fong, Charlene Hui Hua Ramanan, Sharanya Yap, Jasmine Lye Yee Yin, Jocelyn Naixin Yip, Yun Sheng Tan, Wei Ren Koh, Angele Pei Fern Tan, Nguan Soon Chan, Ching Wan Huang, Ruby Yun Ju Li, Jing Ze Fröhlich, Jürg Franco-Obregón, Alfredo |
author_facet | Tai, Yee Kit Chan, Karen Ka Wing Fong, Charlene Hui Hua Ramanan, Sharanya Yap, Jasmine Lye Yee Yin, Jocelyn Naixin Yip, Yun Sheng Tan, Wei Ren Koh, Angele Pei Fern Tan, Nguan Soon Chan, Ching Wan Huang, Ruby Yun Ju Li, Jing Ze Fröhlich, Jürg Franco-Obregón, Alfredo |
author_sort | Tai, Yee Kit |
collection | PubMed |
description | Chemotherapy is the mainstream treatment modality for invasive breast cancer. Unfortunately, chemotherapy-associated adverse events can result in early termination of treatment. Paradoxical effects of chemotherapy are also sometimes observed, whereby prolonged exposure to high doses of chemotherapeutic agents results in malignant states resistant to chemotherapy. In this study, potential synergism between doxorubicin (DOX) and pulsed electromagnetic field (PEMF) therapy was investigated in: 1) MCF-7 and MDA-MB-231 cells in vitro; 2) MCF-7 tumors implanted onto a chicken chorioallantoic membrane (CAM) and; 3) human patient-derived and MCF-7 and MDA-MB-231 breast cancer xenografts implanted into NOD-SCID gamma (NSG) mice. In vivo, synergism was observed in patient-derived and breast cancer cell line xenograft mouse models, wherein PEMF exposure and DOX administration individually reduced tumor size and increased apoptosis and could be augmented by combined treatments. In the CAM xenograft model, DOX and PEMF exposure also synergistically reduced tumor size as well as reduced Transient Receptor Potential Canonical 1 (TRPC1) channel expression. In vitro, PEMF exposure alone impaired the survival of MCF-7 and MDA-MB-231 cells, but not that of non-malignant MCF10A breast cells; the selective vulnerability of breast cancer cells to PEMF exposure was corroborated in human tumor biopsy samples. Stable overexpression of TRPC1 enhanced the vulnerability of MCF-7 cells to both DOX and PEMF exposure and promoted proliferation, whereas TRPC1 genetic silencing reduced sensitivity to both DOX and PEMF treatments and mitigated proliferation. Chronic exposure to DOX depressed TRPC1 expression, proliferation, and responses to both PEMF exposure and DOX in a manner that was reversible upon removal of DOX. TRPC1 channel overexpression and silencing positively correlated with markers of epithelial-mesenchymal transition (EMT), including SLUG, SNAIL, VIMENTIN, and E-CADHERIN, indicating increased and decreased EMT, respectively. Finally, PEMF exposure was shown to attenuate the invasiveness of MCF-7 cells in correlation with TRPC1 expression. We thus demonstrate that the expression levels of TRPC1 consistently predicted breast cancer sensitivity to DOX and PEMF interventions and positively correlated to EMT status, providing an initial rationale for the use of PEMF-based therapies as an adjuvant to DOX chemotherapy for the treatment of breast cancers characterized by elevated TRPC1 expression levels. |
format | Online Article Text |
id | pubmed-8818958 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88189582022-02-08 Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach Tai, Yee Kit Chan, Karen Ka Wing Fong, Charlene Hui Hua Ramanan, Sharanya Yap, Jasmine Lye Yee Yin, Jocelyn Naixin Yip, Yun Sheng Tan, Wei Ren Koh, Angele Pei Fern Tan, Nguan Soon Chan, Ching Wan Huang, Ruby Yun Ju Li, Jing Ze Fröhlich, Jürg Franco-Obregón, Alfredo Front Oncol Oncology Chemotherapy is the mainstream treatment modality for invasive breast cancer. Unfortunately, chemotherapy-associated adverse events can result in early termination of treatment. Paradoxical effects of chemotherapy are also sometimes observed, whereby prolonged exposure to high doses of chemotherapeutic agents results in malignant states resistant to chemotherapy. In this study, potential synergism between doxorubicin (DOX) and pulsed electromagnetic field (PEMF) therapy was investigated in: 1) MCF-7 and MDA-MB-231 cells in vitro; 2) MCF-7 tumors implanted onto a chicken chorioallantoic membrane (CAM) and; 3) human patient-derived and MCF-7 and MDA-MB-231 breast cancer xenografts implanted into NOD-SCID gamma (NSG) mice. In vivo, synergism was observed in patient-derived and breast cancer cell line xenograft mouse models, wherein PEMF exposure and DOX administration individually reduced tumor size and increased apoptosis and could be augmented by combined treatments. In the CAM xenograft model, DOX and PEMF exposure also synergistically reduced tumor size as well as reduced Transient Receptor Potential Canonical 1 (TRPC1) channel expression. In vitro, PEMF exposure alone impaired the survival of MCF-7 and MDA-MB-231 cells, but not that of non-malignant MCF10A breast cells; the selective vulnerability of breast cancer cells to PEMF exposure was corroborated in human tumor biopsy samples. Stable overexpression of TRPC1 enhanced the vulnerability of MCF-7 cells to both DOX and PEMF exposure and promoted proliferation, whereas TRPC1 genetic silencing reduced sensitivity to both DOX and PEMF treatments and mitigated proliferation. Chronic exposure to DOX depressed TRPC1 expression, proliferation, and responses to both PEMF exposure and DOX in a manner that was reversible upon removal of DOX. TRPC1 channel overexpression and silencing positively correlated with markers of epithelial-mesenchymal transition (EMT), including SLUG, SNAIL, VIMENTIN, and E-CADHERIN, indicating increased and decreased EMT, respectively. Finally, PEMF exposure was shown to attenuate the invasiveness of MCF-7 cells in correlation with TRPC1 expression. We thus demonstrate that the expression levels of TRPC1 consistently predicted breast cancer sensitivity to DOX and PEMF interventions and positively correlated to EMT status, providing an initial rationale for the use of PEMF-based therapies as an adjuvant to DOX chemotherapy for the treatment of breast cancers characterized by elevated TRPC1 expression levels. Frontiers Media S.A. 2022-01-24 /pmc/articles/PMC8818958/ /pubmed/35141145 http://dx.doi.org/10.3389/fonc.2021.783803 Text en Copyright © 2022 Tai, Chan, Fong, Ramanan, Yap, Yin, Yip, Tan, Koh, Tan, Chan, Huang, Li, Fröhlich and Franco-Obregón https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Tai, Yee Kit Chan, Karen Ka Wing Fong, Charlene Hui Hua Ramanan, Sharanya Yap, Jasmine Lye Yee Yin, Jocelyn Naixin Yip, Yun Sheng Tan, Wei Ren Koh, Angele Pei Fern Tan, Nguan Soon Chan, Ching Wan Huang, Ruby Yun Ju Li, Jing Ze Fröhlich, Jürg Franco-Obregón, Alfredo Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach |
title | Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach |
title_full | Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach |
title_fullStr | Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach |
title_full_unstemmed | Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach |
title_short | Modulated TRPC1 Expression Predicts Sensitivity of Breast Cancer to Doxorubicin and Magnetic Field Therapy: Segue Towards a Precision Medicine Approach |
title_sort | modulated trpc1 expression predicts sensitivity of breast cancer to doxorubicin and magnetic field therapy: segue towards a precision medicine approach |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818958/ https://www.ncbi.nlm.nih.gov/pubmed/35141145 http://dx.doi.org/10.3389/fonc.2021.783803 |
work_keys_str_mv | AT taiyeekit modulatedtrpc1expressionpredictssensitivityofbreastcancertodoxorubicinandmagneticfieldtherapyseguetowardsaprecisionmedicineapproach AT chankarenkawing modulatedtrpc1expressionpredictssensitivityofbreastcancertodoxorubicinandmagneticfieldtherapyseguetowardsaprecisionmedicineapproach AT fongcharlenehuihua modulatedtrpc1expressionpredictssensitivityofbreastcancertodoxorubicinandmagneticfieldtherapyseguetowardsaprecisionmedicineapproach AT ramanansharanya modulatedtrpc1expressionpredictssensitivityofbreastcancertodoxorubicinandmagneticfieldtherapyseguetowardsaprecisionmedicineapproach AT yapjasminelyeyee modulatedtrpc1expressionpredictssensitivityofbreastcancertodoxorubicinandmagneticfieldtherapyseguetowardsaprecisionmedicineapproach AT yinjocelynnaixin modulatedtrpc1expressionpredictssensitivityofbreastcancertodoxorubicinandmagneticfieldtherapyseguetowardsaprecisionmedicineapproach AT yipyunsheng modulatedtrpc1expressionpredictssensitivityofbreastcancertodoxorubicinandmagneticfieldtherapyseguetowardsaprecisionmedicineapproach AT tanweiren modulatedtrpc1expressionpredictssensitivityofbreastcancertodoxorubicinandmagneticfieldtherapyseguetowardsaprecisionmedicineapproach AT kohangelepeifern modulatedtrpc1expressionpredictssensitivityofbreastcancertodoxorubicinandmagneticfieldtherapyseguetowardsaprecisionmedicineapproach AT tannguansoon modulatedtrpc1expressionpredictssensitivityofbreastcancertodoxorubicinandmagneticfieldtherapyseguetowardsaprecisionmedicineapproach AT chanchingwan modulatedtrpc1expressionpredictssensitivityofbreastcancertodoxorubicinandmagneticfieldtherapyseguetowardsaprecisionmedicineapproach AT huangrubyyunju modulatedtrpc1expressionpredictssensitivityofbreastcancertodoxorubicinandmagneticfieldtherapyseguetowardsaprecisionmedicineapproach AT lijingze modulatedtrpc1expressionpredictssensitivityofbreastcancertodoxorubicinandmagneticfieldtherapyseguetowardsaprecisionmedicineapproach AT frohlichjurg modulatedtrpc1expressionpredictssensitivityofbreastcancertodoxorubicinandmagneticfieldtherapyseguetowardsaprecisionmedicineapproach AT francoobregonalfredo modulatedtrpc1expressionpredictssensitivityofbreastcancertodoxorubicinandmagneticfieldtherapyseguetowardsaprecisionmedicineapproach |